(NUS) Nu Skin Enterprises - Ratings and Ratios
Skin Care, Cosmetics, Nutritional Supplements, Wellness Products, Personal Care
NUS EPS (Earnings per Share)
NUS Revenue
Description: NUS Nu Skin Enterprises
Nu Skin Enterprises Inc is a global developer and distributor of beauty and wellness products, operating through various channels including retail stores, digital platforms, and independent direct sellers. The companys product portfolio includes skin care devices, cosmetics, and nutritional supplements, with popular brands such as ageLOC LumiSpa, LifePak, and Beauty Focus Collagen+.
From a business perspective, Nu Skins diversified product offerings and multi-channel distribution strategy are key strengths. The companys focus on research and product development enables it to stay competitive in the personal care products industry. With a global presence, Nu Skin is well-positioned to capitalize on trends in the beauty and wellness space.
To further analyze Nu Skins performance, key performance indicators (KPIs) such as revenue growth, gross margin, and sales per distributor can be examined. For instance, a steady increase in revenue growth could indicate successful product launches or effective distribution strategies. Additionally, metrics like customer acquisition cost and customer retention rate can provide insights into the companys marketing efficiency and customer loyalty.
From a financial perspective, Nu Skins market capitalization and negative return on equity (RoE) suggest that the company is facing challenges. The absence of P/E ratios may indicate that the company is not generating earnings or is experiencing significant fluctuations in earnings. As a Trading Analyst, it is essential to dig deeper into the companys financials to understand the underlying drivers of its performance and identify potential areas for improvement.
To make informed investment decisions, it is crucial to monitor Nu Skins progress in addressing its challenges and capitalizing on opportunities in the beauty and wellness market. By analyzing KPIs and financial metrics, investors can gain a more comprehensive understanding of the companys prospects and make data-driven decisions.
Additional Sources for NUS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
NUS Stock Overview
| Market Cap in USD | 436m |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| GiC Sub-Industry | Personal Care Products |
| IPO / Inception | 1996-11-21 |
NUS Stock Ratings
| Growth Rating | -75.4 |
| Fundamental | -10.3 |
| Dividend Rating | 17.8 |
| Rel. Strength | -21.9 |
| Analysts | - |
| Fair Price Momentum | 7.58 USD |
| Fair Price DCF | 27.95 USD |
NUS Dividends
| Dividend Yield 12m | 2.96% |
| Yield on Cost 5y | 0.65% |
| Annual Growth 5y | -30.69% |
| Payout Consistency | 96.6% |
| Payout Ratio | 8.3% |
NUS Growth Ratios
| Growth Correlation 3m | 87.4% |
| Growth Correlation 12m | -22.4% |
| Growth Correlation 5y | -92.1% |
| CAGR 5y | -23.95% |
| CAGR/Max DD 5y | -0.27 |
| Sharpe Ratio 12m | -1.60 |
| Alpha | -21.67 |
| Beta | 0.648 |
| Volatility | 62.27% |
| Current Volume | 462.4k |
| Average Volume 20d | 471.8k |
| Stop Loss | 8.8 (-5%) |
As of July 09, 2025, the stock is trading at USD 9.26 with a total of 462,350 shares traded.
Over the past week, the price has changed by +4.51%, over one month by +15.17%, over three months by +54.93% and over the past year by -11.70%.
Neither. Based on ValueRay´s Fundamental Analyses, Nu Skin Enterprises is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -10.28 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NUS is around 7.58 USD . This means that NUS is currently overvalued and has a potential downside of -18.14%.
Nu Skin Enterprises has no consensus analysts rating.
According to our own proprietary Forecast Model, NUS Nu Skin Enterprises will be worth about 8.4 in July 2026. The stock is currently trading at 9.26. This means that the stock has a potential downside of -9.5%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | -19% |
| Analysts Target Price | 7.5 | -19% |
| ValueRay Target Price | 8.4 | -9.5% |